These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 11392005)
41. Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues. Johnston CI; Naitoh M; Burrell LM J Hypertens Suppl; 1997 Dec; 15(7):S3-6. PubMed ID: 9532514 [TBL] [Abstract][Full Text] [Related]
42. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system. Schalekamp MA; Derkx FH; van den Meiracker AH J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650 [TBL] [Abstract][Full Text] [Related]
43. Antihypertensive drugs and fibrinolytic function. Fogari R; Zoppi A Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777 [TBL] [Abstract][Full Text] [Related]
44. ONTARGET still OFF-TARGET? Lambers Heerspink HJ; de Zeeuw D Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820 [No Abstract] [Full Text] [Related]
45. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? de Gasparo M; Levens N Pharmacol Toxicol; 1998 Jun; 82(6):257-71. PubMed ID: 9677617 [TBL] [Abstract][Full Text] [Related]
46. [Angiotensin II receptor antagonists: a review of the development and future perspective]. Saito I; Saruta T Nihon Rinsho; 1999 May; 57(5):1015-9. PubMed ID: 10361427 [TBL] [Abstract][Full Text] [Related]
47. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Weir MR; Henrich WL Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177 [TBL] [Abstract][Full Text] [Related]
48. Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. Moulder JE; Fish BL; Cohen EP Int J Radiat Biol; 1998 Apr; 73(4):415-21. PubMed ID: 9587080 [TBL] [Abstract][Full Text] [Related]
49. The renin-angiotensin system in the breast and breast cancer. Vinson GP; Barker S; Puddefoot JR Endocr Relat Cancer; 2012 Feb; 19(1):R1-19. PubMed ID: 22180497 [TBL] [Abstract][Full Text] [Related]
50. Angiotensin II receptor antagonists. Burnier M; Brunner HR Lancet; 2000 Feb; 355(9204):637-45. PubMed ID: 10696996 [TBL] [Abstract][Full Text] [Related]
51. Therapeutic applications of angiotensin II receptor antagonists. Volpe M; Savoia C; Panina G; Cangianiello S Ann Endocrinol (Paris); 2000 Feb; 61(1):47-51. PubMed ID: 10790592 [TBL] [Abstract][Full Text] [Related]
52. AT1 receptor antagonists: a challenge for ACE inhibitors in diabetic nephropathy. Mogyorosi A; Sonkodi S Diabetes Metab Res Rev; 1999; 15(1):55-8. PubMed ID: 10398547 [TBL] [Abstract][Full Text] [Related]
53. Perindopril: a long-term certainty in treating hypertension. Souček M Vnitr Lek; 2021; 67(2):119-124. PubMed ID: 34074111 [TBL] [Abstract][Full Text] [Related]
54. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Molteni A; Ward WF; Ts'ao CH; Taylor J; Small W; Brizio-Molteni L; Veno PA Curr Pharm Des; 2003; 9(9):751-61. PubMed ID: 12570792 [TBL] [Abstract][Full Text] [Related]
56. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Moulder JE; Fish BL; Cohen EP Curr Pharm Des; 2007; 13(13):1317-25. PubMed ID: 17506717 [TBL] [Abstract][Full Text] [Related]
57. What does the future hold? ACE inhibition, angiotensin II receptor blockade, and diabetic nephropathy. Hollenberg NK Blood Press Monit; 2000; 5 Suppl 2():S3-6. PubMed ID: 11087297 [TBL] [Abstract][Full Text] [Related]
58. [Angiotensin II receptor antagonists as the agents to treat cerebrovascular disease]. Kitazono T; Fujishima M Nihon Rinsho; 1999 May; 57(5):1168-75. PubMed ID: 10419376 [TBL] [Abstract][Full Text] [Related]
59. ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Moulder JE; Fish BL; Cohen EP Curr Pharm Des; 2003; 9(9):737-49. PubMed ID: 12570791 [TBL] [Abstract][Full Text] [Related]